8 reports

OF THESE, ##% OF PATIENTS EXPERIENCE A CHRONIC CONDITION AND ##% OF THESE REQUIRE OPIOIDS FOR PAIN RELIEF.

  • Ovarian Cancer
  • Topical Delivery
  • United States
  • Forecast
  • Nektar Therapeutics

Also additional data showed rapid and sustained pain relief from as early as week ##, which was sustained out to ## years in PsA patients.

  • Biomarker
  • Clinical Trial
  • Ovarian Cancer
  • United States
  • GlobalData's company
  • PAIN, FIVE PATIENTS EXPERIENCED IMPROVEMENT IN PAIN AT WEEK SIX OR WEEK 12 PER INVESTIGATOR REPORT.

In this cohort of patients, the adverse events were headache, diarrhoea, anemia, fatigue, arthralgia (joint pain) and back pain.

  • Cancer
  • Ovarian Cancer
  • United States
  • Product Initiative
  • Merck & Co., Inc.

Exelixis, Inc. reported interim data on pain relief and related reduction in narcotic analgesic use with cabozantinib in castration-resistant prostate cancer (CRPC) patients with bone metastases.

  • Monoclonal Antibody
  • Ovarian Cancer
  • United States
  • Product Initiative
  • Merck & Co., Inc.
  • OVARIAN CANCER - PIPELINE BY GENOR BIOPHARMA CO LTD, H2 2017
  • OVARIAN CANCER - PIPELINE BY GILEAD SCIENCES INC, H2 2017

The company offers over-the-counter (OTC) products for pain relief, oral health, nutrition, skin health and respiratory diseases.

  • Cell Therapy
  • Ovarian Cancer
  • North America
  • United States
  • Product Initiative
  • OVARIAN CANCER - PIPELINE BY GILEAD SCIENCES INC, H1 2017
  • OVARIAN CANCER - PIPELINE BY GLAXOSMITHKLINE PLC, H1 2017

The company offers over-the-counter (OTC) products for pain relief, oral health, nutrition, skin health and respiratory diseases.

  • Cell Therapy
  • Ovarian Cancer
  • North America
  • United States
  • Product Initiative

DIARRHOEA, ANEMIA, FATIGUE, ARTHRALGIA (JOINT PAIN) AND BACK PAIN.

  • Cancer
  • Ovarian Cancer
  • United States
  • Product Initiative
  • Merck & Co., Inc.

The third patient had stable disease on bone scan. ##-Nov-2011 Exelixis, Inc. reported interim data on pain relief and related reduction in narcotic analgesic use with cabozantinib in castration-resistant prostate cancer (CRPC) patients with bone metastases.

  • Ovarian Cancer
  • United States
  • Company
  • Product Initiative
  • Merck & Co., Inc.